故事的三面:医疗保险受益者中SGLT2抑制剂治疗第一年的依从性轨迹
基于2013年4月至2017年12月的医疗保险理赔数据,纳入83,675例66岁及以上新使用SGLT2抑制剂的2型糖尿病患者。第一年平均覆盖天数比例为63%,识别出低(23%,平均PDC 17%)、中(32%,平均PDC 50%)、高(45%,平均PDC 96%)三个依从性轨迹组。女性及黑人种族/族裔与低依从性最强相关。
要点
- 第一年平均覆盖天数比例为63%。
- 依从性轨迹分为低(23%,平均PDC 17%)、中(32%,平均PDC 50%)、高(45%,平均PDC 96%)三组。
- 女性及黑人种族/族裔与低依从性最强相关。
核心结论
- 在大型老年2型糖尿病患者人群中,45%在SGLT2抑制剂治疗第一年高度依从,女性及黑人种族/族裔与低依从性最强相关。
研究设计与样本
- 使用2013年4月至2017年12月的医疗保险理赔数据,识别83,675例66岁及以上新使用SGLT2抑制剂的2型糖尿病患者。
- 以第一年覆盖天数比例(PDC)衡量依从性,采用线性回归评估基线协变量与PDC的关联,采用基于组的轨迹模型识别依从性轨迹组,并采用多变量逻辑回归模型检验基线协变量与轨迹组归属的关联。
主要发现
- 未调整平均PDC为63%。
- 既往他汀类药物依从性与PDC正关联最强(回归系数6.00% [95% CI 5.50, 6.50]),女性(-5.51% [-6.02, -5.00])和黑人种族/族裔(-5.06% [-6.03, -4.09])负关联最强。
- 高依从组中既往他汀依从者更多(比值比1.43 [95% CI 1.39, 1.48]),低依从组中女性(1.28 [1.23, 1.32])和黑人患者(1.31 [1.23, 1.40])更多。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to understand the factors associated with sodium-glucose cotransporter 2 inhibitor (SGLT2i) adherence and longitudinal adherence trajectories in older adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: Using Medicare claims data (April 2013-December 2017), we identified 83,675 new SGLT2i users ≥66 years old with type 2 diabetes. We measured SGLT2i adherence as the proportion of days covered (PDC) during the first year of SGLT2i therapy. We used linear regression to assess the association between baseline covariates and PDC. Then we used group-based trajectory modeling to identify distinct longitudinal SGLT2i adherence groups and used a multivariable logistic regression model to examine the association between baseline covariates and membership in these adherence groups. RESULTS: Unadjusted mean PDC was 63%. Previous adherence to statins had the strongest positive association with PDC (regression coefficient 6.00% [95% CI 5.50, 6.50]), whereas female sex (-5.51% [-6.02, -5.00]), and Black race/ethnicity (-5.06% [-6.03, -4.09]) had the strongest negative association. We identified three adherence trajectory groups: low (23% of patients, mean PDC 17%), moderate (32%, mean PDC 50%), and high (45%, mean PDC 96%) adherence. More patients in the high adherence group were previously adherent to statins (odds ratio 1.43 [95% CI 1.39, 1.48]), and more women (1.28 [1.23, 1.32]) and Black patients (1.31 [1.23, 1.40]) were in the low adherence group. CONCLUSIONS: In a large population of older patients with type 2 diabetes, 45% were highly adherent during the first year of SGLT2i treatment. Female sex and Black race/ethnicity were most strongly associated with low adherence.
引用
- Hawley CE, Lauffenburger JC, Paik JM, et al. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. Diabetes Care. 2022. PMID: 35043165. doi:10.2337/dc21-1676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。